Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

Brussels, Belgium – 2 March 2019 – UCB, a global biopharmaceutical company, presented positive data from the Phase 2b BE ABLE extension study of bimekizumab in patients with moderate-to-severe chronic plaque psoriasis, which showed nearly all BE ABLE 1 responders completing 60 weeks of bimekizumab treatment maintained complete or almost complete skin clearance. The results are the longest-term data so […]

Read more

FDA Approves Adhansia XR

STAMFORD, Conn.–(BUSINESS WIRE) March 01, 2019 –Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII, a central nervous system (CNS) stimulant, for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients six years and older. In a simulated Adult Workplace Environment (AWE) study, Adhansia […]

Read more

FDA Approves Esperoct

Bagsværd, Denmark, 19 February 2019 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for Esperoct for the treatment of adults and children with hemophilia A. Esperoct is the brand name for turoctocog alfa pegol, N8-GP. Esperoct is indicated for use in adults and children with hemophilia A (congenital factor […]

Read more

Acyclovir labeling now includes details for treating premature infants infected with herpes virus

Newborns infected with herpes simplex virus (HSV) can be appropriately treated with acyclovir, a drug typically prescribed to adults for the treatment of HSV infections. Acyclovir’s drug label now includes information for healthcare providers on recommended usage and dosage in newborns up to 3 months of age. The data that informed this label change came from a study funded by […]

Read more

Even in best-case scenario, opioid overdose deaths will keep rising until 2022

In the nation’s opioid epidemic, the carnage is far from over. A new projection of opioid overdose death rates suggests that even if there is steady progress in reducing prescription narcotics abuse nationwide, the number of fatal overdoses—which reached 47,600 in 2017—will rise sharply in the coming years. By 2022, such deaths would peak at about 75,400, and begin to […]

Read more

Antiepileptic drugs linked to increased hospital stays in persons with Alzheimer’s disease

People with Alzheimer’s disease who used antiepileptic drugs had a higher number of accumulated hospital stays than people with Alzheimer’s disease who did not use antiepileptics, according to a new study from the University of Eastern Finland. The results were published in the Journal of American Medical Directors Association. During a two-year follow-up, persons who initiated antiepileptic drugs accumulated approximately […]

Read more

Opioid addiction is a public health crisis—the way we’re talking about it isn’t helping.

The misuse of and addiction to opioids is a public health crisis in the United States. Part of solving that crisis, say two Northeastern researchers, is changing how we talk about addiction. Leo Beletsky, an associate professor at Northeastern who studies opioid addiction, and Zachary Siegel, a doctoral candidate who’s working with him, are creating “Change the Narrative,” a guide […]

Read more

New report reveals stark north-south divide in painkiller prescribing in England

A new report has revealed that patients in the north of the country are being prescribed almost four times more opioids to relieve pain than those in the south. The research by the University of Nottingham’s School of Pharmacy and the University of Manchester is the first national study to examine the regional variations in opioid prescribing and how this […]

Read more

After naloxone, when can opioid overdose patients be safely discharged?

Naloxone has saved thousands of lives. But can patients be safely discharged from the Emergency Department (ED) just an hour after they receive the medication that curtails drug overdoses? According to the St. Paul’s Early Discharge Rule developed in 2000, that’s how long providers should observe patients after naloxone treatment, so long as their vital signs meet specific criteria and […]

Read more

Lynparza (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer

19 December 2018 — AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved Lynparza for use as maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal […]

Read more
1 2 3 6